Company Performance Metrics
Andrew Barofsky: Co-Founder, President, Chief Executive Officer & Board Member
Obstetrx creates a uterine tamponade device to eliminate maternal death and disability from postpartum hemorrhage. In 2014, RevMedx, Inc. developed the XSTAT® hemorrhage-control device in concert with the US military to stop severe bleeding from non-compressible wounds suffered on the battlefield. They soon realized that this type of traumatic
bleeding, which XSTAT has been proven successful in treating, is highly analogous to postpartum hemorrhage. Inspired to address this global issue in women’s health, the team quickly got to work adapting the combat medicine technology for an obstetric application.
RevMedx partnered with a team from Oregon Health & Science University, who received a Saving Lives at Birth Grand Challenge grant to conduct early-stage research and development. This work culminated in a pre-clinical proof-of-concept study. With the inception of Obstetrx, Inc, a pilot clinical trial was performed in Zambia in 2019.
Today, Obstetrx is a privately-held company based in Wilsonville, OR. We are currently working toward regulatory clearance and commercialization of our novel uterine tamponade device in the US and across the globe.
